Replies to post #1933 on Spectrum Pharmaceutecals Inc (SPPI)

[stugwins]

pK studies on a 351a pathway are usually many many years ahead of BLA submission.

What is really the objective of this pK study? Bridging to a reference drug is a slippery slope since it could trigger a "patent dance" and would trigger the issue of similarity.